Eli Lilly's Next-Gen Obesity Drug Retatrutide Already Circulating in Gray Market Before FDA Approval

Compounding pharmacies are replicating and selling retatrutide before Phase 3 trials conclude — adverse event reports are already emerging.

Eli Lilly's next-generation obesity drug retatrutide (Retatrutide) is already being distributed through U.S. compounding pharmacies in a gray market — before the company has received FDA approval. With the Phase 3 TRIUMPH trial not expected to conclude until May 2026, compounders have leveraged publicly available patent disclosures to manufacture and sell copies of the drug, primarily through online channels.

Why Is It Already on the Market Before Approval?

Retatrutide is currently in Phase 3 trials under the TRIUMPH designation. Once patent information became publicly available at trial initiation, compounding pharmacies moved quickly to replicate and sell the compound.

Because compounding pharmacy sales are not outright illegal in the United States, experts classify this as a 'gray market' rather than a black market. The drug has already gained enough consumer traction to earn a street name — "Retda" — among users.

Clinical Data Is Driving Demand

Unlike existing GLP-1 class drugs, retatrutide is a triple agonist that simultaneously targets three hormone receptors.

• Retatrutide: average weight loss of 28.7% at maximum dose over 68 weeks
• Zepbound (tirzepatide, Lilly's existing product): average 20.2% over 72 weeks
• Indications under evaluation: obesity, knee osteoarthritis, renal and hepatic disease, type 2 diabetes, and lower back pain

By the numbers alone, it is the most potent next-generation candidate in the GLP-1 drug class.

Discontinuation Rate Triple That of Zepbound

The efficacy data is compelling, but safety concerns are significant.

• Discontinuation rate due to adverse events at maximum dose: 18.2%
• Zepbound discontinuation rate: 6.1% (roughly one-third the level)
• Gray market compounded product users have reported severe gastrointestinal distress and acute nausea

Given that Lilly is developing the drug primarily for clinically obese patients with a BMI of 35 or above, unsupervised use by non-clinical populations carries substantially greater risk.

The greatest danger with pre-approval compounded products is self-administration of a drug with unverified dosing, purity, and excipients — outside any normal medical supervision.

Lilly and Platforms Push Back, But Revenue Cannibalization Risk Remains

Lilly has declared a hardline stance against the distribution of unapproved compounded versions of its drug. TikTok and Meta have both moved to suspend seller accounts on their platforms. Enforcement was stepped up after a Channel 4 (UK) investigative report revealed that purchases were being facilitated through social media.

For investors, however, the core risk is distinct. If the market becomes saturated with compounded versions before FDA approval, legitimate commercial sales post-launch could face meaningful revenue cannibalization.

The obesity and diabetes drug market is projected to reach approximately $100 billion by the 2030s, with Novo Nordisk also developing a comparable triple agonist. Expanding Medicare coverage for obesity treatments adds further tailwinds to overall market growth — but the extent to which the gray market has already captured a share of future official launch revenues remains a critical unknown for investors.